Li Zhang, Md
Clinical trials sponsored by Li Zhang, Md, explained in plain language.
-
Triple therapy targets tough lung cancer
Disease control OngoingThis phase II trial is testing whether a combination of surufatinib (a targeted therapy), toripalimab (an immunotherapy), and standard chemotherapy can help people with advanced non-squamous non-small cell lung cancer. The study enrolls adults with stage IIIB or IV disease who ha…
Phase: PHASE2 • Sponsor: Li Zhang, MD • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New combo therapy aims to outsmart tough lung cancer mutations
Disease control OngoingThis phase 3 trial compares the standard drug osimertinib alone versus osimertinib combined with two chemotherapy drugs (carboplatin and pemetrexed) as a first treatment for people with advanced non-squamous lung cancer that has both EGFR and TP53 mutations. The study involves 29…
Phase: PHASE3 • Sponsor: Li Zhang, MD • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC